Crescent Biopharma, Inc.
CBIO
$14.47
-$0.23-1.57%
NASDAQ
| 06/30/2025 | |||||
|---|---|---|---|---|---|
| Net Income | -43.85% | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 513.00% | ||||
| Change in Net Operating Assets | -170.45% | ||||
| Cash from Operations | -51.16% | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -- | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | 2,885,520.00% | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 285.11% | ||||
| Cash from Financing | 9,983.18% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 1,156.35% | ||||